Ann E. Berman - 13 Jun 2025 Form 4 Insider Report for Immuneering Corp (IMRX)

Reporting relationship: Director
Issuer ticker: IMRX
Reported as of: 13 Jun 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 16 Jun 2025, 08:54:39 UTC
Prior SEC filing: 03 Jun 2025
Next SEC filing: 01 Jul 2025
Source filing: View source filing
Reporting owner signature: By: /s/ Michael D. Bookman, Attorney-in-Fact for Ann E. Berman

Key filing fact

Ann E. Berman filed Form 4 for Immuneering Corp (IMRX) on 16 Jun 2025.

Key facts

This page summarizes Ann E. Berman's Form 4 filing for Immuneering Corp (IMRX).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 16 Jun 2025, 08:54.

Change

Previous filing in this sequence was filed on 03 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001349408 Primary reporting owner

BERMAN ANN E

Relationship: Director
Address: 245 MAIN STREET, SECOND FLOOR, CAMBRIDGE
Signature: By: /s/ Michael D. Bookman, Attorney-in-Fact for Ann E. Berman
Signature date: 16 Jun 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

IMRX transaction Derivative

Stock Option

Award

Transaction value: $0
Shares: +33,350
Change %
Price: $0.000000
Shares after: 33,350
Date: 13 Jun 2025
Ownership: Direct
Underlying class: Class A Common Stock
Underlying amount: 33,350
Exercise price: $1.90
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The option vests and becomes exercisable in equal monthly installments over a one-year period commencing on July 13, 2025, and will be fully vested and exercisable on June 13, 2026, or the date of the 2026 annual meeting of stockholders, whichever comes first.